Abstract

Galectin-1 (Gal-1) is a 14 kDa protein that has been well characterized for promoting cancer metastasis and tumor immune evasion. By localizing to the cancer cell surface, Gal-1 induces T cell apoptosis through binding T cell surface receptors. The transmembrane protein, Sushi Domain Containing 2 (SUSD2), has been previously shown to be required for Gal-1 surface presentation in breast cancer cells. Western immunoblot analysis revealed that SUSD2 is cleaved into two fragments. However, the significance of this cleavage for Gal-1 surface localization has not been investigated. To define the location of cleavage, a mutagenesis analysis of SUSD2 was performed. Our studies demonstrated that SUSD2 is cleaved at its glycine-aspartic acid-proline-histidine (GDPH) amino acid sequence. Generation of a noncleavable SUSD2 mutant (GDPH∆-SUSD2) showed that SUSD2 cleavage was required for SUSD2 and Gal-1 plasma membrane localization. Noncleavable cysteine mutants were also unable to present Gal-1 at the cell surface, further demonstrating that SUSD2 cleavage is required for Gal-1 surface presentation. Treatment with the serine protease inhibitor, Pefabloc SC, inhibited SUSD2 cleavage in a dose dependent manner, suggesting that SUSD2 is cleaved by a serine protease. Therefore, identification and inhibition of this protease may provide a new therapeutic tool for inhibiting SUSD2 and Gal-1′s combined tumorigenic function in breast cancer.

Highlights

  • Sushi Domain Containing 2 (SUSD2) has been studied in cancer, neurodevelopment, and as a marker for mesenchymal stem cells

  • Sushi Domain Containing 2 (SUSD2) is a type I transmembrane protein that is required for Gal-1 cell surface presentation

  • Our data suggests that SUSD2 cleavage is likely mediated by a serine protease

Read more

Summary

Introduction

Sushi Domain Containing 2 (SUSD2) has been studied in cancer, neurodevelopment, and as a marker for mesenchymal stem cells. SUSD2 has been described as both protumor [1,2] and antitumor [3,4] depending on the type of cancer. SUSD2 has been identified as the antigen for the W5C5 antibody, which is used as a marker for the isolation of mesenchymal stem cells from human tonsil and bone marrow [6,7]. While SUSD2 has been studied in diverse biological systems, there are currently few studies on the biochemical properties of the protein. Knowledge of the structure and post-translational processing of SUSD2 may prove useful in determining the functions of the protein in association with health and disease

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call